In February 2026, WuXi AppTec quietly appeared on a U.S. list of "Chinese military companies"—then vanished within the hour, no explanation given. Four months later, it was back for good. This third episode of Pharma Talk unpacks how a contract research giant that does R&D for drugmakers worldwide ended up branded a national-security threat, and why the U.S. campaign to sever it keeps failing.

We trace the economics that make China indispensable to global drug development, explain how the BIOSECURE Act quietly mutated from a congressional blacklist into a Pentagon "revolving door" list, and show why—despite the label—WuXi's U.S. order book was already at record highs before the hand ever fell. The episode ends in a D.C. courtroom, where the very carelessness of that on-again, off-again listing became WuXi's sharpest argument against it. The bigger question underneath all three episodes: when the logic of efficiency collides with political will, who wins?

How did COVID reshape US-China biotech dealmaking without creating a single new incentive? This episode traces the capital rollercoaster and the Moderna myth that turned China's biotech sector from platform-dreamers into the world's most efficient discovery engine — in just three years.

Chinese volume-based procurement and America's drug-pricing reforms were never meant to work together — yet these two unrelated domestic policies quietly reshaped the global pharmaceutical value chain. This episode traces how China became the world's discovery engine while the US kept development and commercialization, driving a surge in licensing deals that reached a record $137.7 billion in 2025.

The 2026 BIO International Convention marked a turning point: for the first time, biotechnology was framed squarely as a matter of national security. This episode breaks down BIO CEO John Crowley's argument for why US innovation must confront Chinese competition head-on — from the "offensive" playbook of FDA modernization and tax incentives, to the "defensive" one of the BIOSECURE Act and outbound-investment controls. It also examines why Crowley, who could have played the easy anti-China card, instead points to America's own "man-made problems," and why he sees AI widening the divide between large and small players. A bilingual, two-sided look at a story being told very differently on each side of the Pacific.The 2026 BIO International Convention marked a turning point: for the first time, biotechnology was framed squarely as a matter of national security. This episode breaks down BIO CEO John Crowley's argument for why US innovation must confront Chinese competition head-on — from the "offensive" playbook of FDA modernization and tax incentives, to the "defensive" one of the BIOSECURE Act and outbound-investment controls. It also examines why Crowley, who could have played the easy anti-China card, instead points to America's own "man-made problems," and why he sees AI widening the divide between large and small players. A bilingual, two-sided look at a story being told very differently on each side of the Pacific.